Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biotron ( (AU:BIT) ) has issued an update.
Biotron Limited has completed the first stage of an animal study for its lead drug targeting Hepatitis B Virus (HBV), confirming the drug’s safety in mice. The study, conducted at the SCRIPPS Research Institute, aims to assess the antiviral activity of the drug in two mouse models, with the next phase focusing on its efficacy in treating HBV infection. This development is a significant step forward in Biotron’s HBV program, which seeks to address the global health challenge posed by chronic HBV infections. Concurrently, Biotron is advancing its commercialisation efforts, engaging with potential partners at industry events to further its programs, including those focused on HIV-1.
More about Biotron
Biotron Limited is a company focused on the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical needs. The company has BIT225 in clinical development for HIV-1 and COVID-19, and additional promising preclinical programs including Hepatitis B Virus (HBV). Biotron also works on designing drugs targeting viroporins, which are crucial in the virus life cycle of various viruses such as Coronavirus, Dengue, Ebola, and others.
Technical Sentiment Signal: Sell
Current Market Cap: A$2.65M
For an in-depth examination of BIT stock, go to TipRanks’ Overview page.